Xeris Biopharma Holdings (XERS) Receivables (2020 - 2026)

Xeris Biopharma Holdings has reported Receivables for 7 years, with the latest figure at $56.3 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables rose 21.51% year-over-year to $56.3 million; the trailing twelve-month figure through Mar 2026 stood at $56.3 million (up 21.51% YoY), and the FY2025 full-year result was $51.0 million, up 26.31% from the prior year.
• Receivables for Q1 2026 stood at $56.3 million, up from $51.0 million in the prior quarter.
• The five-year high for Receivables was $56.3 million in Q1 2026, with the low at $23.4 million in Q1 2022.
• Historically, Receivables has averaged $39.7 million across 5 years, with a median of $40.4 million in 2024.
• Annual changes were most pronounced in 2022 — Receivables surged 102.92% — and 2024, when it dropped 10.5%.
• Xeris Biopharma Holdings' Receivables stood at $30.8 million in 2022, then increased by 27.14% to $39.2 million in 2023, then rose by 3.11% to $40.4 million in 2024, then rose by 26.31% to $51.0 million in 2025, then grew by 10.27% to $56.3 million in 2026.
• The last three Receivables figures came in at $56.3 million (Q1 2026), $51.0 million (Q4 2025), and $53.8 million (Q3 2025), per Business Quant data.